Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect Zevra Therapeutics to post earnings of ($0.21) per share and revenue of $16.96 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Price Performance

NASDAQ ZVRA traded up $0.08 on Friday, reaching $7.87. The company had a trading volume of 363,460 shares, compared to its average volume of 619,878. The stock has a market capitalization of $430.32 million, a PE ratio of -3.99 and a beta of 1.87. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm's 50 day moving average price is $7.52 and its 200 day moving average price is $8.07.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZVRA. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim upped their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $22.29.

Insider Buying and Selling at Zevra Therapeutics

In related news, EVP Joshua Schafer sold 10,500 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at approximately $231,759.96. This represents a 26.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at $318,400. This trade represents a 33.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 85,773 shares of company stock worth $674,176 over the last quarter. Insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.